T. Rowe Price Investment Management, Inc.

Position in IMNM — Immunome Inc.

CIK 1897612 BALTIMORE, MD

Position in IMNM

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$416,953,150

+$59,072,230 QoQ

Shares Held

19,676,883

+20.2% QoQ

Ownership

17.3%

of shares outstanding

% of Portfolio

0.27%

of 13F equity value

Holder Rank

of 200 holders

Holding Since

Mar 2024

10 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

T. Rowe Price Investment Management, Inc. holds $12,244,164,567 across 51 Biotechnology names. IMNM ranks #8 (3.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ASND	Ascendis Pharma A/S	6,754,846	$1,801,652,525
2	ALNY	Alnylam Pharmaceuticals, Inc.	5,642,173	$1,698,463,338
3	CYTK	Cytokinetics Inc	18,718,498	$1,594,628,844
4	KYMR	Kymera Therapeutics, Inc.	6,257,261	$717,520,118
5	PCVX	Vaxcyte, Inc.	12,207,450	$709,619,068
6	DYN	Dyne Therapeutics, Inc.	30,912,287	$686,561,894
7	CGON	CG Oncology, Inc.	6,616,899	$470,130,673
8	IMNM	Immunome Inc. This page	19,676,883	$416,953,150

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$416,953,150	19,676,883	+84.9%	Shares	Sole	2026-08-14
2026-06-30	$416,953,150	19,676,883	+20.2%	Shares	Sole	2026-08-14
2026-03-31	$357,880,920	16,364,011	+1245.1%	Shares	Sole	2026-05-15
2025-12-31	$26,131,558	1,216,553	-85.5%	Shares	Sole	2026-02-17
2025-10-31	$171,059,911	10,644,674	—	Shares	Sole	2025-11-07
2025-09-30	$98,576,688	8,418,163	+1.7%	Shares	Sole	2025-11-14
2025-06-30	$76,959,890	8,275,257	+9.5%	Shares	Sole	2025-08-14
2025-03-31	$50,842,417	7,554,594	+37.4%	Shares	Sole	2025-05-14
2024-12-31	$58,409,511	5,499,954	-4.5%	Shares	Sole	2025-02-14
2024-09-30	$84,240,630	5,762,013	+48.6%	Shares	Sole	2024-11-14
2024-06-30	$46,930,999	3,878,595	+155.8%	Shares	Sole	2024-08-14
2024-03-31	$37,426,084	1,516,454	—	Shares	Sole	2024-05-15
No filing history on record for this holder in this stock.